The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital, part of HCA Healthcare, has received internationally-recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) for adult autologous transplantation and immune effector cell therapy (IECT).
FACT is an internationally-recognized accrediting body for programs offering blood and marrow transplant, sometimes called stem cell transplant or bone marrow transplant, and IECT which includes CAR T-cell therapy, a therapy which uses the immune system to target cancer cells. This indicates the accredited institution has met the most rigorous standards in the entire therapy spectrum from clinical care to donor management, cell collection, transportation, processing, storage, cell release, and administration.
The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital, which opened in 2021, is the only such program in the state of Nevada.
“This is a significant milestone for our program,” said Dr. Shahram Mori, Transplant and Cellular Therapy Clinical Program Medical Director. “Since our launch we have been able to offer the complete continuum of care for blood-related malignancies here in Las Vegas. Prior to our launch, 100 percent of adult patients had to leave the state. FACT accreditation validates the safe, quality care provided to our patients with complex blood cancers.”
The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital includes a dedicated inpatient unit and outpatient clinic. As part of the Sarah Cannon Transplant & Cellular Therapy Network, programs are brought together through physician-led blood cancer programs across the United States and United Kingdom and is one of the largest providers of transplant and cellular therapies in the world.
“MountainView Hospital started on this journey in order to provide our community and the larger state of Nevada an option for complex treatments so they wouldn’t have to leave the state,” said Hiral Patel, MountainView Hospital Chief Executive Officer. “This international accreditation validates that we provide our patients the highest quality and most comprehensive services available for complex blood disorders, and that patients should feel comfortable receiving this care in their home community. Our FACT-accreditation and partnership with the Sarah Cannon Transplant & Cellular Therapy network exemplifies that commitment and expands the treatment options available to people living with blood cancer.”
Two transplant and cellular therapy veterans lead the program at MountainView Hospital - Dr. Delva Deauna-Limayo as the BMT Clinical Program Medical Director and Dr. Shahram Mori as the Transplant and Cellular Therapy Program Medical Director. The program continues to expand and will soon begin offering CAR T-Cell therapy and eventually allogeneic transplant.
The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital is part of the Sarah Cannon Transplant & Cellular Therapy Network, offering patients convenient, community-based access to complex blood cancer care including acute leukemia, blood and marrow transplantation, clinical trials and innovative therapies. The Network treats approximately 1,600 transplant and cellular therapy patients annually across its nine FACT/JACIE accredited programs in the United States and United Kingdom.
Patients and physicians who want to learn more about MountainView’s program can call (702) 962-2106.